EGFR and non-small cell lung carcinoma: The median TMBs of the four groups were 5.6, 2.3, 8.1, and 8.2 muts/Mb, respectively, displaying a lower TMB in patients with EGFR or ALK-fusion mutation compared to wild-type (WT) NSCLC (p < 0.001) (Figure 2A).